20012-10-6

Usage

Synonym

Tetrahydroberberine hydrobromide

Derived from

Natural alkaloid berberine

Usage

Pharmaceutical research

Potential treatment for

Diabetes, obesity, cardiovascular disease

Properties

Potent anti-inflammatory, antioxidant

Effects on

Glucose and lipid metabolism

Structure

Promising candidate for new medications

Further research needed

Mechanisms of action, therapeutic applications

Upstream product

• 20011-97-6 N-[2-(3,4-dimethoxyphenyl)ethyl]-2-phenyl-2-hydroxyethylamine 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 96-09-3 styrene oxide 

Downstream Products

• 135974-59-3 3-formyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 135974-58-2 3-allyl-6,9-dichloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 104114-24-1 (R,S)-7,8-dihydroxy-1H-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 104422-04-0 SKF 77434 

Relevant academic research and scientific papers

Dopamine Agonists Related to 3-Allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol. 6-Position Modifications

The N-allyl derivative (SK and F 85174) of 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol (SK and F 82526) retains the DA-1 agonist potency of the latter compound but unlike the parent also shows substantial DA-2 agonist activity.In a previous study of N-substituted benzazepines these combined agonist effects were shown to be uniquely associated with the N-allyl group.A continuation of this research has examined dependency of combined DA-2/DA-1 agonist activities on 6=position modification with the specific objective of developing an agonist with maximum effectiveness and potency at the DA-2 receptor subtype.DA-2 agonist activity was measured in a rabbit ear artery assay, and DA-1 agonist activity was determined in an adenylate cyclase assay.Replacing chloro with bromo retains the activity pattern and the potency of the chloro compound: replacement with a hydrogen causes a decrease of both DA-1 and DA-2 receptor activating potency.Introduction of a 6-methyl group causes loss of DA-2 agonist activity and reduction in DA-1 agonist potency.Substitution with a 6-fluoro provides the best balance of DA-2 and DA-1 agonist activities; this compound was moderately in both assays.

PHARMACEUTICAL COMPOSITIONS AND METHODS INVOLVING BENZAZEPINE DERIVATIVES

Pharmaceutical compositions and a method of stimulating peripheral dopamine receptors by administering internally a nontoxic effective quantity of a benzazepine derivative to an animal. Renal vasodilator and diuretic methods are also disclosed.

Pharmaceutical compositions and method of producing anti-Parkinsonism activity

Pharmaceutical compositions and method of producing anti-Parkinsonism activity by administering internally a nontoxic effective quantity of a benzazepine derivative to an animal.